Abstract
A previously published clinical trial demonstrated the benefit of autologous CD34+ cells transduced with a selfinactivating lentiviral vector (HPV569) containing an engineered β-globin gene (βA-T87Q-globin) in a subject with β thalassemia major. This vector has been modified to increase transduction efficacy without compromising safety. In vitro analyses indicated that the changes resulted in both increased vector titers (3 to 4 fold) and increased transduction efficacy (2 to 3 fold). An in vivo study in which 58 β-thalassemic mice were transplanted with vector- or mock-transduced syngenic bone marrow cells indicated sustained therapeutic efficacy. Secondary transplantations involving 108 recipients were performed to evaluate long-term safety. The six month study showed no hematological or biochemical toxicity. Integration site (IS) profile revealed an oligo/polyclonal hematopoietic reconstitution in the primary transplants and reduced clonality in secondary transplants. Tumor cells were detected in the secondary transplant mice in all treatment groups (including the control group), without statistical differences in the tumor incidence. Immunohistochemistry and quantitative PCR demonstrated that tumor cells were not derived from transduced donor cells. This comprehensive efficacy and safety data provided the basis for initiating two clinical trials with this second generation vector (BB305) in Europe and in the USA in patients with β-thalassemia major and sickle cell disease.
Keywords: β-hemoglobinopathy, β-thalassemia, gene therapy, lentiviral vector, mouse model.
Current Gene Therapy
Title:Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Volume: 15 Issue: 1
Author(s): Christophe Joubert, Gabor Veres, Emmanuel Payen, Christof von Kalle, Manfred Schmidt, Byoung Ryu, Michael Rothe, Francis J. Pierciey, Anais Paulard, Leila Maouche, Philippe Leboulch, Robert Kutner, Olivier Negre, Beatrix Gillet-Legrand, Raffaele Fronza, Mitchell Finer, Edouard de Dreuzy, Maria Denaro, Annette Deichmann, Celine Courne, Lauryn Christiansen, Marina Cavazzana, Yves Beuzard and Cynthia Bartholomae
Affiliation:
Keywords: β-hemoglobinopathy, β-thalassemia, gene therapy, lentiviral vector, mouse model.
Abstract: A previously published clinical trial demonstrated the benefit of autologous CD34+ cells transduced with a selfinactivating lentiviral vector (HPV569) containing an engineered β-globin gene (βA-T87Q-globin) in a subject with β thalassemia major. This vector has been modified to increase transduction efficacy without compromising safety. In vitro analyses indicated that the changes resulted in both increased vector titers (3 to 4 fold) and increased transduction efficacy (2 to 3 fold). An in vivo study in which 58 β-thalassemic mice were transplanted with vector- or mock-transduced syngenic bone marrow cells indicated sustained therapeutic efficacy. Secondary transplantations involving 108 recipients were performed to evaluate long-term safety. The six month study showed no hematological or biochemical toxicity. Integration site (IS) profile revealed an oligo/polyclonal hematopoietic reconstitution in the primary transplants and reduced clonality in secondary transplants. Tumor cells were detected in the secondary transplant mice in all treatment groups (including the control group), without statistical differences in the tumor incidence. Immunohistochemistry and quantitative PCR demonstrated that tumor cells were not derived from transduced donor cells. This comprehensive efficacy and safety data provided the basis for initiating two clinical trials with this second generation vector (BB305) in Europe and in the USA in patients with β-thalassemia major and sickle cell disease.
Export Options
About this article
Cite this article as:
Joubert Christophe, Veres Gabor, Payen Emmanuel, Kalle von Christof, Schmidt Manfred, Ryu Byoung, Rothe Michael, Pierciey J. Francis, Paulard Anais, Maouche Leila, Leboulch Philippe, Kutner Robert, Negre Olivier, Gillet-Legrand Beatrix, Fronza Raffaele, Finer Mitchell, Dreuzy de Edouard, Denaro Maria, Deichmann Annette, Courne Celine, Christiansen Lauryn, Cavazzana Marina, Beuzard Yves and Bartholomae Cynthia, Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127095336
DOI https://dx.doi.org/10.2174/1566523214666141127095336 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular and Cellular Mechanism of Cutaneous Injuries Due to Exposure to Sulfur Mustard
Letters in Drug Design & Discovery Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Editorial
Current Pharmaceutical Biotechnology Lactoferricin Derived From Milk Protein Lactoferrin
Current Pharmaceutical Design A Reliable HPLC Method for Monitoring Midazolam Plasma Levels in Critically Ill Pediatric Patients
Current Pharmaceutical Analysis Chromosomal Aberrations and Genomic Instability Induced by Topoisomerase- Targeted Antitumour Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Cancer and Stem Cells
Current Cancer Therapy Reviews Developmental Regulated Expression of Anti- and Pro-Apoptotic BCL-2 Family Genes During Human Early Embryonic Development
Current Medicinal Chemistry Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Unveiling Cancer in IBD: Screening Colonoscopy or Chromoendoscopy
Current Drug Targets Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Current Topics in Medicinal Chemistry A Dilemma of Functional Genomics: Count the Chickens or Study their Eggs ?
Current Genomics Anti - TNF Therapy for Crohns Disease
Current Pharmaceutical Design Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations
Current Angiogenesis (Discontinued)